Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diseases of the Colon & Rectum
Published in: Diseases of the Colon & Rectum 1/2006

01-10-2006 | Current Status

Efficacy of Oral Anticancer Agents for Colorectal Cancer

Authors: Junichi Sakamoto, M.D., Ph.D., Koji Oba, M.S., Takanori Matsui, M.D., Ph.D., Michiya Kobayashi, M.D., Ph.D.

Published in: Diseases of the Colon & Rectum | Special Issue 1/2006

Login to get access

Excerpt

Development of oral anticancer agents was long awaited by both physicians and patients. It can be taken for granted that most patients prefer oral intake to injection of such drugs if the efficacy of the former is equivalent or superior to that of parenteral agents.1 In terms of quality of life and cost-effectiveness, oral agents are obviously superior to parenteral drugs, which necessitate hospitalization or a long stay in the outpatient ward for their injection. …
Literature
1.
Borner, MM, Schoffski, P, Wit, R,  et al. 2002Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerEur J Cancer38349358PubMedCrossRef
2.
Hahn, RG, Moertel, CG, Schutt, AJ, Bruckner, HW 1975A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinomaCancer3510311035PubMedCrossRef
3.
Friedman, MA, Ignoffo, RJ 1980A review of the United States clinical experience of the fluoropyridimine, Ftorafur (NSC-148958)Cancer Treat Rev7205213PubMedCrossRef
4.
Sakamoto, J, Hamada, C, Kodaira, S, Nakazato, H, Ohashi, Y 1999Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trialsJpn J Clin Oncol297886PubMedCrossRef
5.
Hoshi, A, Iigo, M, Yoshida, M, Kuretani, K 1975Antitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administrationGann66673674PubMed
6.
Hoshi, A, Iigo, M, Nakamura, A, Yoshida, M, Kuretani, K 1976Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumorsGann67725731PubMed
7.
HCFU Clinical Study Group1980Absorption and excretion of new oral antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), in cancer patientsJpn J Clin Oncol108392
8.
Iigo, M, Hoshi, A, Nakamura, A, Kuretani, K 1978Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumorsCancer Chemother Pharmacol1203208PubMedCrossRef
9.
Koyama, Y 19811-hexylcarbamoyl-5-fluorouracil (HCFU): a masked 5-fluorinated pyrimidineCancer Treat Rev8147156PubMed
10.
11.
Kono, A, Hara, Y, Sugata, S, Karube, Y, Matsushima, Y, Ishitsuka, H 1983Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumorsChem Pharm Bull (Tokyo)31175178
12.
Kikkawa, N, Taguchi, T, Sakai, K,  et al. 1993Combination therapy of high dose doxifluridine (5′-DFUR) + mitomycin C (MMC) for advanced or recurrent colorectal cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5′-DFUR with Other Drugs [in Japanese]Gan To Kagaku Ryoho20117123PubMed
13.
Malik, ST, Talbot, D, Clarke, PI,  et al. 1990Phase II trial of UFT in advanced colorectal and gastric cancerBr J Cancer6210231025PubMed
14.
Ota, K, Taguchi, T, Kimura, K 1987Report on nationwide pooled data and cohort investigation in UFT Phase II study [in Japanese]Gan To Kagaku Ryoho1427492757PubMed
15.
Pazdur, R, Lassere, Y, Diaz-Canton, E, Ho, DH 1998Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day scheduleCancer Invest16145151PubMed
16.
Anonymous1992Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis ProjectJ Clin Oncol10896903
17.
Pazdur, R, Lassere, Y, Rhodes, V,  et al. 1994Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinomaJ Clin Oncol1222962300PubMed
18.
Ichikawa, W, Nihei, Z, Uetake, H, Yamada, H, Shirota, Y, Sugihara, K 2000UFT plus leucovorin for metastatic colorectal cancer: Japanese experienceOncology (Williston Park)144143
19.
Carmichael, J, Popiela, T, Radstone, D,  et al. 2002Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol2036173627PubMedCrossRef
20.
Douillard, J-Y, Hoff, PM, Skillings, JR,  et al. 2002Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol2036053616PubMedCrossRef
21.
Shirao, K, Hoff, PM, Ohtsu, A,  et al. 2004Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LVJ Clin Oncol2234663474PubMedCrossRef
22.
Miwa, M, Ura, M, Nishida, M,  et al. 1998Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEur J Cancer3412741281PubMedCrossRef
23.
Takebayashi, Y, Akiyama, S, Akiba, S,  et al. 1996Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinomaJ Natl Cancer Inst8811101117PubMed
24.
Cutsem, E, Findlay, M, Osterwalder, B,  et al. 2000Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II studyJ Clin Oncol1813371345PubMed
25.
Cutsem, E, Twelves, C, Cassidy, J,  et al. 2001Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyJ Clin Oncol1940974106PubMed
26.
Hoff, PM, Ansari, R, Batist, G,  et al. 2001Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III studyJ Clin Oncol1922822292PubMed
27.
Cassidy, J, Tabernero, J, Twelves, C,  et al. 2004XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJ Clin Oncol2220842091PubMedCrossRef
28.
Scheithauer, W, Kornek, GV, Raderer, M,  et al. 2003Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol2113071312PubMedCrossRef
29.
Feliu, J, Escudero, P, Llosa, F,  et al. 2005Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group studyJ Clin Oncol2331043111PubMedCrossRef
30.
Hofheinz, RD, Gerstenberg-Helldorf, B, Wenz, F,  et al. 2005Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancerJ Clin Oncol2313501357PubMedCrossRef
31.
Shirasaka, T, Shimamato, Y, Ohshimo, H,  et al. 1996Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnticancer Drugs7548557PubMedCrossRef
32.
Tatsumi, K, Fukushima, M, Shirasaka, T, Fujii, S 1987Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extractsJpn J Cancer Res78748755PubMed
33.
Groeningen, CJ, Peters, GJ, Schornagel, JH,  et al. 2000Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumorsJ Clin Oncol1827722779PubMed
34.
Hoff, PM, Saad, ED, Ajani, JA,  et al. 2003Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumorsClin Cancer Res9134142PubMed
35.
Chu, QS, Hammond, LA, Schwartz, G,  et al. 2004Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesClin Cancer Res1049134921PubMedCrossRef
36.
Brande, J, Schoffski, P, Schellens, JH,  et al. 2003EORTC Early Clinical Studies Group. Early phase II trial of S-1 in patients with advanced or metastatic colorectal cancerBr J Cancer88648653PubMedCrossRef
37.
Taguchi, T, Inuyama, Y, Kanamaru, R,  et al. 1997Phase I study of S-1. S-1 Study Group [in Japanese]Gan To Kagaku Ryoho2422532264PubMed
38.
Ohtsu, A, Baba, H, Sakata, Y,  et al. 2000Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study GroupBr J Cancer83141145PubMedCrossRef
39.
Shirao, K, Ohtsu, A, Takada, H,  et al. 2004Phase II study of oral S-1 for treatment of metastatic colorectal carcinomaCancer10023552361PubMedCrossRef
40.
Komatsu, Y, Yuuki, S, Fuse, N,  et al. 2005Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302Jpn J Clin Oncol358889PubMedCrossRef
41.
Matsuda, T, Yasutomi, M, Kikuchi, K,  et al. 1991Cooperative study of surgical adjuvant chemotherapy for colorectal cancer: five year results [in Japanese]Gan To Kagaku Ryoho18461469PubMed
42.
Anonymous1995Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of JapanJpn J Clin Oncol2591103
43.
Ito, K, Yamaguchi, A, Miura, K,  et al. 1996Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-upJ Surg Oncol63107111PubMedCrossRef
44.
Sakamoto, J, Hamada, C, Kodaira, S, Nakazato, H, Ohashi, Y 1999Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trialsJpn J Clin Oncol297886PubMedCrossRef
45.
Sakamoto, J, Kodaira, S, Hamada, C,  et al. 2001An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancerOncol Rep8697703PubMed
46.
Sakamoto, J, Ohashi, Y, Hamada, C,  et al. 2004Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trialsJ Clin Oncol22484492PubMed
47.
Kodaira, S, Kikuchi, K, Yasutomi, M,  et al. 1998Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer: results from the Cooperative Project No.7 Group of the Japanese Foundation for Multidisciplinary Treatment of CancerInt J Clin Oncol3357364CrossRef
48.
Yasutomi, M, Takahashi, T, Kodaira, S,  et al. 1997Prospective controlled study of the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancerGan To Kagaku Ryoho2419531960PubMed
49.
Wolmark, N, Colangelo, L, Wieand, S 2001National Surgical Adjuvant Breast and Bowel Project trials in colon cancerSemin Oncol28913PubMedCrossRef
50.
Wolmark, N, Wieand, S, Lembersky, B, Colangelo, L, Smith, R, Pazdur, R 2004A Phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06Proc Am Soc Clin Oncol (Post-Meeting Edition)22247
51.
Akasu, T, Moriya, Y, Yoshida, S,  et al. 2004Adjuvant oral uracil and tegafur (UFT) improves survival after complete mesorectal excision (ME) for pathologic TNM stage III rectal cancer (RC): results of the National Surgical Adjuvant Study (NSAS)-Colorectal Cancer (CC) 01 randomized trialProc Am Soc Clin Oncol (Post-Meeting Edition)22251
52.
Sakamoto, J, Hamada, C, Yasutomi, M,  et al. 2005An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancerJpn J Clin Oncol35536544PubMedCrossRef
53.
Twelves, C, Wong, A, Nowacki, MP,  et al. 2005Capecitabine as adjuvant treatment for stage III colon cancerN Engl J Med3522696704PubMedCrossRef
Metadata
Title
Efficacy of Oral Anticancer Agents for Colorectal Cancer
Authors
Junichi Sakamoto, M.D., Ph.D.
Koji Oba, M.S.
Takanori Matsui, M.D., Ph.D.
Michiya Kobayashi, M.D., Ph.D.
Publication date
01-10-2006
Publisher
Springer-Verlag
Published in
Diseases of the Colon & Rectum / Issue Special Issue 1/2006
Print ISSN: 0012-3706
Electronic ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-006-0601-7

Other articles of this Special Issue 1/2006

Diseases of the Colon & Rectum 1/2006 Go to the issue

EditorialNotes

Editorial

OriginalPaper

Frequency of Immunohistochemical Loss of Mismatch Repair Protein in Double Primary Cancers of the Colorectum and Stomach in Japan

OriginalPaper

Intersphincteric Resection in Patients with Very Low Rectal Cancer: A Review of the Japanese Experience

OriginalPaper

A Preliminary Study of the Draining Lymph Node Basin in Advanced Lower Rectal Cancer Using a Radioactive Tracer

OriginalPaper

Factors Affecting Recurrence in Patients with Crohn’s Disease Under Nutritional Therapy

OriginalPaper

Site-Specific Patterns of Surgical Site Infections and Their Early Indicators After Elective Colorectal Cancer Surgery